盐酸伊托必利分散片联合泮托拉唑钠肠溶片治疗反流性食管炎的临床疗效  

Clinical efficacy of itopride hydrochloride dispersible tablets combined with pantoprazole sodium entericcoated tablets in the treatment of reflux esophagitis

作　　者：袁陈婷 孙锦秀 郭晶晶 YUAN Chenting;SUN Jinxiu;GUO Jingjing(Department of Pharmacy,Rugao Hospital Affiliated to Nantong University/Rugao People's Hospital,Nantong,Jiangsu,226500,China)

机构地区：[1]南通大学附属如皋医院/如皋市人民医院药剂科,江苏南通226500

出　　处：《当代医学》2023年第19期48-51,共4页Contemporary Medicine

摘　　要：目的探讨盐酸伊托必利分散片联合泮托拉唑钠肠溶片治疗反流性食管炎(RE)的临床疗效及对炎症因子水平的影响。方法选取2019年1月至2020年12月如皋市人民医院收治的66例RE患者作为研究对象,按照随机数字表法分为两组,各33例。对照组予以盐酸伊托必利分散片治疗,观察组在对照组基础上联合泮托拉唑钠肠溶片治疗,比较两组临床疗效、炎症因子水平、临床症状评分及不良反应发生情况。结果观察组治疗总有效率为93.94%,高于对照组的75.76%,差异有统计学意义(P<0.05)。治疗后,观察组C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)水平分别为(6.13±1.04)mg/L、(20.04±3.15)μg/L、(62.13±7.59)ng/L,均低于对照组的(8.65±1.13)mg/L、(26.51±3.22)μg/L、(70.34±7.82)ng/L,差异有统计学意义(P<0.05)。治疗后,观察组反酸、烧心及胸骨后疼痛评分分别为(0.65±0.11)、(0.55±0.09)、(0.71±0.13)分,均低于对照组的(1.02±0.19)、(0.93±0.14)、(1.12±0.22)分,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论盐酸伊托必利分散片联合泮托拉唑钠肠溶片治疗RE效果显著,可减轻机体炎症反应,加快发酸等症状消失,安全可靠。Objective To investigate the clinical efficacy of itopride hydrochloride dispersible tablets combined with pantoprazole sodium enteric-coated tablets in the treatment of reflux esophagus(RE)and its influence on the level of inflammatory factors.Methods A total of 66 RE patients admitted to Rugao People's Hospital from January 2019 to December 2020 were selected as the research subjects,and they were divided into two groups according to the random number table method,with 33 cases in each group.The control group was treated with itopride hydrochloride dispersible tablets,and the observation group was treated with pantoprazole sodium enteric-coated tablets on the basis of the control group,the clinical efficacy,inflammatory factor levels,clinical symptom scores and adverse reactions were compared between the two groups.Results The total effective rate in the observation group was 93.94%,which was higher than 75.76%in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of the C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in the observation group were(6.13±1.04)mg/L,(20.04±3.15)mg/L and(62.13±7.59)ng/L,respectively,which was lower than(8.65±1.13)mg/L,(26.51±3.22)μg/L,(70.34±7.82)ng/L in the control group,the differences were statistically significant(P<0.05).After treatment,the scores of acid reflux,heartburn and retrosternal pain in the observation group were(0.65±0.11),(0.55±0.09),(0.71±0.13)scores,which were lower than(1.02±0.19),(0.93±0.14),(1.12±0.22)scores in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Itopride hydrochloride dispersible tablets combined with pantoprazole sodium enteric-coated tablets have significant effect in the treatment of RE,can reduce the inflammatory reaction of the body,accelerate the disappearance of acidosis and other symptoms,which is safe and reliable.

关 键 词：反流性食管炎 盐酸伊托必利分散片 泮托拉唑钠肠溶片 炎症因子 不良反应 

分 类 号：R571[医药卫生—消化系统]